Document registry — page 26
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised crossover, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2024 -
Consultation on the policy governing how the Institute cites evidence. The draft requires that every citation resolve to a retrievable source, that an identifier the…
05 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low04 Oct 2024 -
Peptides, SARMs, injectable oils and raw materials.
03 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low02 Oct 2024 -
Consultation on the draft of this intervention review, which registers the question: What is the effect of an amylin receptor agonist alone and in combination with a…
26 Sep 2024 -
Consultation on the draft monograph for AOD-9604, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Sep 2024 -
Peptides, SARMs and raw materials. 350+ catalogue lines.
25 Sep 2024 -
Diagnostic accuracy study of Gonadorelin in gh axis over single test. Primary result: An established diagnostic stimulation test. The Institute records that the…
Moderate22 Sep 2024 -
Record of documents ratified in the 2024 Q3 assessment cycle.
18 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Single-arm open-label study of Thymalin in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 Sep 2024 -
What can be concluded from a development programme that was discontinued, and how should the Institute record it?
Moderate09 Sep 2024 -
Consultation on the draft monograph for Gonadorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
08 Sep 2024 -
Consultation on the policy governing how the Institute corrects a published document and how versions are numbered, retained and linked. The draft retains every…
06 Sep 2024 -
Observational study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low06 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Sep 2024 -
Consultation on the draft of this analytical evidence review, which registers the question: How large is the discrepancy between labelled peptide mass and delivered…
01 Sep 2024 -
Growth-hormone-releasing hormone analogue. Tesamorelin stimulates the pituitary to release endogenous growth hormone in a pulsatile pattern, preserving the physiological feedback architecture…
Moderate01 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low31 Aug 2024 -
Peptides, SARMs, injectable oils and raw materials.
28 Aug 2024 -
Consultation on the draft monograph for Hexarelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
27 Aug 2024 -
GLP-1 receptor agonist (acylated, once-daily). Receptor pharmacology is that of the selective GLP-1 class. The pharmacokinetic engineering differs: self-association into heptamers at the…
High27 Aug 2024 -
What is the evidence that glucagon-like peptide-1 receptor agonism increases the risk of medullary thyroid carcinoma in humans?
Low23 Aug 2024 -
Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.
21 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Aug 2024 -
Related-substances profiling and the detection of isobaric impurities
High19 Aug 2024 -
Observational, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Aug 2024 -
GLP-1 receptor agonist (acylated, long-acting). Semaglutide is a full agonist at the glucagon-like peptide-1 receptor, a class B G protein-coupled receptor signalling principally through Gαs and…
High16 Aug 2024 -
Melanocortin receptor agonist (cyclic heptapeptide). Bremelanotide activates central melanocortin-4 receptors, acting on hypothalamic and limbic circuits regulating sexual desire. Unlike…
Moderate15 Aug 2024 -
Unimolecular amylin and GLP-1 receptor co-agonist. A single peptide engineered to activate both the amylin and GLP-1 receptor systems, combining two complementary satiation mechanisms without the…
Low11 Aug 2024 -
Consultation on the draft monograph for Kisspeptin-10, which the assessment committee released for public comment before ratification. The draft grades the compound's…
10 Aug 2024 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over up to 12 weeks. The Institute holds no reported primary result for this record and publishes no…
Very low09 Aug 2024 -
Randomised crossover, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Aug 2024 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Aug 2024 -
Consultation on the second version of the framework the Institute uses to rate certainty in a body of evidence. The revision retains the four-level GRADE scale and…
04 Aug 2024
page 26 of 41